TIC-TAC-SAM « Comparison of two strategies of etoposide initiation in severe sporadic hemophagocytic lymphohistiocytosis in intensive care: a randomized trial »
This study, called TIC-TAC-SAM, is for adults in intensive care with a serious, rare immune condition called Hemophagocytic Lymphohistiocytosis (HLH). We're comparing two ways of giving a common chemotherapy medicine, etoposide, along with steroids (dexamethasone). One group receives etoposide sooner, and the other receives it a bit later, only if needed. The main goal is to find out which approach is better at stopping or reversing damage to organs like the kidneys, lungs, or heart. We also look at how long people stay in intensive care, how much medicine they need, and how their blood tests improve. All participants are closely monitored by their medical team.
At a glance
What is this study about?
This research study, called TIC-TAC-SAM, is looking at how best to treat a very serious and rare condition called Hemophagocytic Lymphohistiocytosis (HLH). HLH happens when the body's immune system overreacts and starts attacking its own organs and tissues. This can lead to inflammation and damage throughout the body, making people very unwell, often requiring care in an intensive care unit (ICU).
The study wants to find out the best way to give a medicine called etoposide, which is a type of chemotherapy, together with steroids like dexamethasone. Both are used to calm down the overactive immune system in HLH. We are comparing two different approaches: giving etoposide earlier versus giving it a bit later, only if the patient's condition isn't improving or gets worse. The main thing we're looking at is whether one approach is better at preventing new organ problems or making existing ones worse.
To check this, doctors will carefully monitor how different organs are working. They will use a special scoring system to see if any organs show signs of stress or damage. They will also keep track of other important things like how long patients stay in the ICU, how long they need breathing support, and if their blood tests (which show inflammation and organ function) get better. The aim is to improve care for patients with this life-threatening condition.
Key takeaways
- This study compares two ways of giving etoposide for severe HLH in ICU patients.
- It aims to find the best timing for treatment to protect organs.
- Both etoposide and dexamethasone are standard medicines for HLH.
- Your care will be closely monitored by your medical team in the ICU.
- Participation will not involve extra hospital visits beyond your usual care.
- You can stop participating at any time without affecting your medical treatment.
Who may be eligible?
This study is for adults who are 18 years old or older. Both men and women can take part.
To be eligible, you must be in an intensive care unit (ICU) and have been diagnosed with a severe form of Hemophagocytic Lymphohistiocytosis (HLH) that developed suddenly, rather than being inherited from your family.
Your medical team will check other specific health details to make sure this study is right and safe for you, as not everyone with HLH may be able to join. They will make sure that the treatment plan in the study matches your individual needs and current health situation.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you currently in an intensive care unit (ICU)?
- Have you been diagnosed with severe HLH that wasn't passed down in your family?
- Has your medical team confirmed that this study is suitable for your specific health situation?
What does participation involve?
If you join this study, you will continue to receive care in the intensive care unit. You will be randomly put into one of two groups. Both groups will receive dexamethasone (a steroid) and etoposide (a chemotherapy drug) to treat your HLH, but the timing of etoposide will be different. One group will start etoposide sooner, while the other will start it later, only if needed.
Your medical team will closely monitor your health using regular checks, blood tests, and other assessments for up to 60 days. This includes looking at how your organs are working, whether you need breathing support, how long you stay in intensive care, and how your blood test results change over time. The study will mainly focus on the first 14 days of treatment to see how well the different approaches are working. You will not need extra visits beyond your normal hospital care, as all monitoring will happen as part of your existing treatment in the ICU.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is HLH?
HLH is a rare but serious condition where your immune system becomes overactive and harms your own organs.
What medicines are used in this study?
The study uses two medicines called etoposide (a chemotherapy) and dexamethasone (a steroid), both of which help calm the immune system.
Why are two groups being compared?
The study wants to find out if starting etoposide treatment earlier or a bit later works better in preventing organ damage.
Will I have extra appointments if I join?
No, all monitoring for the study will happen as part of your existing care in the intensive care unit.
What if I feel unwell during the study?
Your medical team will be closely monitoring you and will adapt your care as needed, just as they would with any patient in intensive care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.